Fidia Farmaceutici SpA and Akorn, Inc. sign Letter of Intent to develop four ANDA drug products for commercialization.

Fidia strengthens its presence in the North American market.

13/10/2005 - Company news

Fidia Farmaceutici S.p.A. and Akorn Inc. (USA) today announced that they have signed a Letter of Intent, to develop four ANDA drug products.

The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Fidia.

The four ANDA drug products include one ointment product, one cream product, and two tablet formulation products used in the immuno compromised anti-viral market.

The combined current market size of the four drugs is approximately $1.0 billion.